



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration  
Silver Spring MD 20993

NDA 021343/S-018  
NDA 021379/S-014  
NDA 021488/S-015  
NDA 021731/S-010

**SUPPLEMENT APPROVAL**

sanofi-aventis U.S., LLC  
55 Corporate Drive  
Bridgewater, NJ 08807

Attention: Ketan Patel, Senior Manager  
US Regulatory Affairs Marketed Products  
sanofi-aventis, Inc.  
On behalf of sanofi-aventis U.S. LLC

Dear Mr. Patel:

Please refer to your Supplemental New Drug Applications (sNDA) dated March 10, 2010, received March 10, 2010; March 12, 2010, received March 12, 2010; and March 19, 2010, received March 19, 2010, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Eligard® (leuprolide acetate for injectable suspension), 7.5 mg, 22.5 mg, 30 mg, and 45 mg.

We also acknowledge receipt of your submissions dated April 21(2), and April 22(2), 2010.

These Prior Approval supplemental new drug applications provide for draft labeling according to the Physician's Labeling Rule (PLR) format, the addition of Section 17 Patient Counseling Information, the inclusion of Section 8.3 Use In Specific Populations – Nursing Mothers, and minor editorial changes.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at

NDA 021343/S-018

NDA 021379/S-014

NDA 021488/S-015

NDA 021731/S-010

Page 2

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

NDA 021343/S-018  
NDA 021379/S-014  
NDA 021488/S-015  
NDA 021731/S-010  
Page 3

## **LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program  
Office of Special Health Issues  
Food and Drug Administration  
10903 New Hampshire Ave  
Building 32, Mail Stop 5353  
Silver Spring, MD 20993

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Kim J. Robertson, Consumer Safety Officer, at (301) 796-1441.

Sincerely,

*{See appended electronic signature page}*

Robert L. Justice, M.D., M.S.  
Director  
Division of Drug Oncology Products  
Office of Oncology Drug Products  
Center for Drug Evaluation and Research

Enclosure  
Content of Labeling

---

**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**

---

/s/

---

ROBERT L JUSTICE  
10/05/2010